VKTX Stock Price, Viking Therapeutics Inc Quote, Chart

Market Summary

USD66.54-1.41

Market Closed

-2.08%

VKTX Stock Price

View Fullscreen

VKTX RSI Chart

VKTX Valuation

Market Cap

6.7B

Price/Earnings (Trailing)

-77.84

Price/Free Cashflow

-91.13

VKTX Price/Sales (Trailing)

VKTX Profitability

Return on Equity

-24.65%

Return on Assets

-23.31%

Free Cashflow Yield

-1.1%

VKTX Fundamentals

VKTX Earnings

Earnings (TTM)

-85.9M

Earnings Growth (Yr)

-25.8%

Earnings Growth (Qtr)

-9.19%

Breaking Down VKTX Revenue

Last 7 days

-7.1%

Last 30 days

5.0%

Last 90 days

217.8%

Trailing 12 Months

226.5%

How does VKTX drawdown profile look like?

VKTX Financial Health

Current Ratio

19.19

VKTX Investor Care

Shares Dilution (1Y)

28.14%

Diluted EPS (TTM)

-0.92

Tracking the Latest Insider Buys and Sells of Viking Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 27, 2024	mancini marianna	acquired	-	-	31,667	chief operating officer
Mar 27, 2024	zante greg	sold (taxes)	-1,384,280	83.34	-16,610	chief financial officer
Mar 27, 2024	mancini marianna	sold (taxes)	-1,384,280	83.34	-16,610	chief operating officer
Mar 27, 2024	lian brian	acquired	-	-	221,667	president & ceo
Mar 27, 2024	zante greg	acquired	-	-	31,667	chief financial officer
Mar 27, 2024	lian brian	sold (taxes)	-12,830,000	83.34	-153,948	president & ceo
Mar 01, 2024	lian brian	sold (taxes)	-13,875,100	85.22	-162,815	president & ceo
Mar 01, 2024	zante greg	sold (taxes)	-1,712,330	85.22	-20,093	chief financial officer
Mar 01, 2024	lian brian	acquired	-	-	221,667	president & ceo
Mar 01, 2024	mancini marianna	sold (taxes)	-1,445,160	85.22	-16,958	chief operating officer

Which funds bought or sold VKTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 16, 2024	180 WEALTH ADVISORS, LLC	sold off	-100	-182,800	-	-%
Apr 16, 2024	Stratos Wealth Partners, LTD.	new	-	257,070	257,070	-%
Apr 16, 2024	Perpetual Ltd	new	-	78,586,200	78,586,200	0.77%
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	new	-	607,292	607,292	-%
Apr 15, 2024	Legato Capital Management LLC	reduced	-55.25	594,132	1,205,560	0.14%
Apr 15, 2024	Pallas Capital Advisors LLC	added	3.84	955,833	1,223,180	0.05%
Apr 12, 2024	DNB Asset Management AS	new	-	609,104	609,104	-%
Apr 12, 2024	Dynamic Advisor Solutions LLC	new	-	287,410	287,410	0.01%
Apr 11, 2024	SALEM INVESTMENT COUNSELORS INC	sold off	-100	-1,238,120	-	-%
Apr 11, 2024	Profit Investment Management, LLC	reduced	-48.6	4,400,020	7,878,640	4.45%

Are Funds Buying or Selling VKTX?

Are funds buying VKTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VKTX

No. of Funds

Unveiling Viking Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	viking global investors lp	5.1%	5,145,112	SC 13G/A
Feb 13, 2024	vanguard group inc	5.38%	5,381,904	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 26, 2024	blackrock inc.	7.6%	7,605,867	SC 13G
Jan 24, 2024	state street corp	5.73%	5,732,990	SC 13G/A
Jan 12, 2024	millennium management llc	0.4%	403,556	SC 13G/A
Nov 02, 2023	viking global investors lp	5.9%	5,858,532	SC 13G
Apr 10, 2023	fmr llc	-	0	SC 13G
Mar 30, 2023	ligand pharmaceuticals inc	4.6%	3,616,077	SC 13D/A
Feb 14, 2023	arrowmark colorado holdings llc	0.02%	15,931	SC 13G/A

Recent SEC filings of Viking Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 05, 2024	ARS	ARS
Apr 05, 2024	DEF 14A	DEF 14A
Apr 05, 2024	DEFA14A	DEFA14A
Mar 27, 2024	4	Insider Trading
Mar 27, 2024	4	Insider Trading
Mar 27, 2024	4	Insider Trading
Mar 26, 2024	8-K	Current Report
Mar 04, 2024	4	Insider Trading
Mar 04, 2024	8-K	Current Report
Mar 04, 2024	4	Insider Trading

Peers (Alternatives to Viking Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.5B	6.8B	-0.79%	-27.48%	-8.38	5.77	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-1.45%	-27.97%	-41.56	10.01	76.23%	61.08%
BMRN	17.1B	2.4B	7.98%	-8.04%	101.85	7.06	15.42%	18.43%
INCY	11.8B	3.7B	-8.07%	-28.58%	19.8	3.2	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-14.74%	-41.61%	-10.94	14.59	425.83%	18.94%
BBIO	4.4B	-	-10.03%	65.15%	-6.73	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-3.97%	-4.38%	-13.79	12.2	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.12%	-12.78%	-46.24	3.9	40.45%	71.62%
ARWR	2.8B	240.7M	-19.94%	-25.89%	-9.4	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.9B	398.2M	-0.50%	-10.21%	26.41	4.74	85.90%	-14.05%
NVAX	544.4M	983.7M	-24.32%	-58.17%	-1	0.55	-50.36%	17.16%
CRBP	389.6M	881.7K	-10.79%	209.42%	-8.73	466.16	-77.61%	-5.33%
INO	258.5M	4.9M	3.17%	4.73%	-1.91	53.11	-54.97%	51.71%
IBIO	6.6M	2.1M	79.05%	74.07%	-0.24	2.14	-13.45%	66.37%

Viking Therapeutics Inc News

Latest updates

Viking Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-3.7%	368	383	401	151	169	167	182	195	211	224	238	250	257	264	271	277	284	290	294	300	302
Current Assets	-3.7%	367	381	399	149	167	165	180	193	211	224	238	250	256	263	271	276	284	289	294	299	302
Cash Equivalents	49.3%	56.00	37.00	70.00	18.00	37.00	29.00	16.00	12.00	26.00	11.00	9.00	17.00	29.00	4.00	19.00	15.00	8.00	31.00	19.00	14.00	25.00
Liabilities	39.2%	20.00	14.00	15.00	17.00	23.00	15.00	16.00	13.00	9.00	11.00	13.00	13.00	12.00	10.00	9.00	9.00	7.00	7.00	6.00	6.00	5.00
Current Liabilities	42.7%	19.00	13.00	13.00	16.00	22.00	14.00	15.00	11.00	9.00	11.00	13.00	13.00	12.00	10.00	9.00	9.00	7.00	6.00	6.00	5.00	5.00
Shareholder's Equity	-5.4%	348	368	386	134	145	151	165	182	202	213	225	237	244	254	262	268	277	283	288	295	298
Retained Earnings	-7.0%	-377	-353	-330	-311	-292	-272	-256	-239	-223	-210	-197	-182	-168	-157	-147	-138	-128	-121	-115	-107	-102
Additional Paid-In Capital	0.6%	734	729	725	453	445	432	430	428	426	424	423	420	413	411	410	407	406	405	404	402	401
Shares Outstanding	0.1%	100	100	100	79.00	78.00	77.00	77.00	77.00	77.00	77.00	76.00	75.00	73.00	72.00	72.00	72.00	72.00	72.00	-	-	-
Float	-	-	-	94.00	-	-	-	196	-	-	-	417	-	-	-	470	-	-	-	535	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	10.3%	-17,640	-19,658	-11,435	-24,643	-10,926	-13,499	-13,442	-10,530	-12,350	-10,926	-13,434	-10,876	-5,486	-5,323	-6,666	-4,302	-11,743	-3,398	-6,459	-3,152	-2,679
Share Based Compensation	-8.9%	4,080	4,481	4,620	3,569	2,156	1,940	2,220	2,357	1,433	1,599	1,491	1,577	1,043	1,474	1,648	1,652	976	811	922	1,034	618
Cashflow From Investing	385.1%	35,733	-12,534	-204,483	2,198	7,260	26,894	18,980	1,619	27,410	13,617	3,560	-6,627	30,269	-9,634	9,780	11,152	-11,061	15,154	10,979	-7,609	-142,391
Cashflow From Financing	354.1%	188	-74.00	267,078	4,184	10,749	10.00	-1,590	-5,006	47.00	-256	1,898	5,191	464	37.00	416	33.00	229	73.00	260	325	343
Buy Backs	-	-	-	-	-	-	-	1,674	5,121	-	-	-	-	-	-	-	-	-	-	-	-	-

VKTX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenues	$ 0	$ 0	$ 0
Operating expenses:
Research and development	63,806	54,234	44,981
General and administrative	37,021	16,121	10,701
Total operating expenses	100,827	70,355	55,682
Loss from operations	(100,827)	(70,355)	(55,682)
Other income (expense):
Amortization of financing costs	(88)	(59)	(18)
Interest income, net	15,020	1,589	703
Realized loss on investments, net	0	(42)	0
Foreign exchange gain	0	0	7
Total other income, net	14,932	1,488	692
Net loss	(85,895)	(68,867)	(54,990)
Other comprehensive loss, net of tax:
Unrealized gain (loss) on securities	742	(295)	(495)
Foreign currency translation loss	29	258	0
Comprehensive loss	$ (85,182)	$ (69,420)	$ (55,485)
Basic net loss per common share	$ (0.91)	$ (0.90)	$ (0.71)
Weighted-average shares used to compute basic net loss per share	94,346,991	76,833,630	77,197,680
Diluted net loss per common share	$ (0.91)	$ (0.90)	$ (0.71)
Weighted-average shares used to compute diluted net loss per share	94,346,991	76,833,630	77,197,680

VKTX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 55,516	$ 36,632
Short-term investments – available for sale	306,563	118,853
Prepaid clinical trial and preclinical study costs	2,624	8,144
Prepaid expenses and other current assets	2,522	3,411
Total current assets	367,225	167,040
Right-of-use assets	1,126	1,418
Deferred financing costs	106	38
Deposits	33	33
Total assets	368,490	168,529
Current liabilities:
Accounts payable	7,512	8,529
Other accrued liabilities	11,299	13,114
Lease liability, current	324	304
Total current liabilities	19,135	21,947
Lease liability, net of current portion	936	1,260
Total long-term liabilities	936	1,260
Total liabilities	20,071	23,207
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.00001 par value: 10,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022
Common stock, $0.00001 par value: 300,000,000 shares authorized at December 31, 2023 and 2022; 100,113,770 shares issued and outstanding at December 31, 2023 an 78,257,258 shares issued and outstanding at December 31, 2022	1	1
Treasury stock at cost, 2,193,251 shares at December 31, 2023 and 2022	(6,795)	(6,795)
Additional paid-in capital	733,546	445,267
Accumulated deficit	(377,944)	(292,049)
Accumulated other comprehensive loss	(389)	(1,102)
Total stockholders’ equity	348,419	145,322
Total liabilities and stockholders’ equity	$ 368,490	$ 168,529

About Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRÃƒÅ¸), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRÃƒÅ¸ for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

CEO	Dr. Brian Lian Ph.D.
WEBSITE	vikingtherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	22

Viking Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Viking Therapeutics Inc? What does VKTX stand for in stocks?

VKTX is the stock ticker symbol of Viking Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Viking Therapeutics Inc (VKTX)?

As of Wed Apr 17 2024, market cap of Viking Therapeutics Inc is 6.69 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VKTX stock?

You can check VKTX's fair value in chart for subscribers.

What is the fair value of VKTX stock?

You can check VKTX's fair value in chart for subscribers. The fair value of Viking Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Viking Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VKTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Viking Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether VKTX is over valued or under valued. Whether Viking Therapeutics Inc is cheap or expensive depends on the assumptions which impact Viking Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VKTX.